Needham & Company LLC Reaffirms “Buy” Rating for NextCure (NASDAQ:NXTC)

Needham & Company LLC restated their buy rating on shares of NextCure (NASDAQ:NXTC) in a research report released on Friday, Benzinga reports. Needham & Company LLC currently has a $4.00 price target on the stock.

Separately, HC Wainwright restated a buy rating and issued a $8.00 price objective on shares of NextCure in a research report on Friday.

NextCure Stock Up 7.8 %

NXTC traded up $0.12 on Friday, reaching $1.65. The company had a trading volume of 129,103 shares, compared to its average volume of 231,066. NextCure has a 1 year low of $0.98 and a 1 year high of $2.57. The stock has a market capitalization of $46.15 million, a PE ratio of -0.75 and a beta of 0.54. The stock has a 50-day moving average price of $1.72 and a 200-day moving average price of $1.40.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02. As a group, analysts expect that NextCure will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

Several institutional investors have recently made changes to their positions in NXTC. Assenagon Asset Management S.A. purchased a new position in shares of NextCure in the 1st quarter valued at about $952,000. Cable Car Capital LLC acquired a new position in NextCure during the fourth quarter worth about $702,000. Marquette Asset Management LLC purchased a new position in NextCure in the fourth quarter valued at about $66,000. Finally, Acuitas Investments LLC lifted its position in shares of NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after acquiring an additional 85,982 shares during the period. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.